Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay
Ester López, Ebene R. Haycroft, Amy Adair, et al.
JCI Insight (2021) Vol. 6, Iss. 16
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies
Gabriele Cerutti, Micah Rapp, Yicheng Guo, et al.
Structure (2021) Vol. 29, Iss. 7, pp. 655-663.e4
Open Access | Times Cited: 57
Modeling SARS-CoV-2 spike/ACE2 protein–protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context
Vincenzo Tragni, Francesca Preziusi, Luna Laera, et al.
The EPMA Journal (2022) Vol. 13, Iss. 1, pp. 149-175
Open Access | Times Cited: 39
Free Energy Perturbation Calculations of Mutation Effects on SARS-CoV-2 RBD::ACE2 Binding Affinity
Alina P. Sergeeva, Phinikoula S. Katsamba, Junzhuo Liao, et al.
Journal of Molecular Biology (2023) Vol. 435, Iss. 15, pp. 168187-168187
Open Access | Times Cited: 17
E484K and N501Y SARS-CoV 2 spike mutants Increase ACE2 recognition but reduce affinity for neutralizing antibody
Sandipan Chakraborty
International Immunopharmacology (2021) Vol. 102, pp. 108424-108424
Open Access | Times Cited: 41
Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development
Franziska Günl, Angeles Mecate‐Zambrano, Selina Rehländer, et al.
Vaccines (2021) Vol. 9, Iss. 10, pp. 1052-1052
Open Access | Times Cited: 29
Diminishing Immune Responses against Variants of Concern in Dialysis Patients 4 Months after SARS-CoV-2 mRNA Vaccination
Alex Dulovic, Monika Strengert, Gema Morillas Ramos, et al.
Emerging infectious diseases (2022) Vol. 28, Iss. 4, pp. 743-750
Open Access | Times Cited: 22
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine
Georgia Deliyannis, Nicholas A. Gherardin, Chinn Yi Wong, et al.
EBioMedicine (2023) Vol. 92, pp. 104574-104574
Open Access | Times Cited: 13
Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants
Ebene R. Haycroft, Samantha K. Davis, Pradhipa Ramanathan, et al.
Medical Microbiology and Immunology (2023) Vol. 212, Iss. 4, pp. 291-305
Open Access | Times Cited: 11
Preexisting immunity restricts mucosal antibody recognition of SARS-CoV-2 and Fc profiles during breakthrough infections
Kevin J. Selva, Pradhipa Ramanathan, Ebene R. Haycroft, et al.
JCI Insight (2023) Vol. 8, Iss. 18
Open Access | Times Cited: 11
Evaluation of a Multiplex Bead Assay against Single-Target Assays for Detection of IgG Antibodies to SARS-CoV-2
Kaitlin F. Mitchell, Christina M. Carlson, Douglas Nace, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 3
Open Access | Times Cited: 16
RAGE Is a Receptor for SARS-CoV-2 N Protein and Mediates N Protein–induced Acute Lung Injury
Jie Xia, Jiangmei Wang, Liyang Ying, et al.
American Journal of Respiratory Cell and Molecular Biology (2023) Vol. 69, Iss. 5, pp. 508-520
Open Access | Times Cited: 9
Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor
Wan Ni Chia, Chee Wah Tan, Aaron Tan, et al.
Science Advances (2023) Vol. 9, Iss. 30
Open Access | Times Cited: 8
Comparative Magnitude and Persistence of Humoral SARS-CoV-2 Vaccination Responses in the Adult Population in Germany
Alex Dulovic, Barbora Kessel, Manuela Harries, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 12
Low pre-existing endemic human coronavirus (HCoV-NL63)-specific T cell frequencies are associated with impaired SARS-CoV-2-specific T cell responses in people living with HIV
Tiza L. Ng’uni, Vernon Musale, Thandeka Nkosi, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 2
Tear antibodies to SARS‐CoV‐2: implications for transmission
Kevin J. Selva, Samantha K. Davis, Ebene R. Haycroft, et al.
Clinical & Translational Immunology (2021) Vol. 10, Iss. 11
Open Access | Times Cited: 16
Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
Bruce D. Wines, Liriye Kurtovic, Halina M. Trist, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 11
Assessment of the binding interactions of SARS-CoV-2 spike glycoprotein variants
Deepa Raghu, Pamela Hamill, Arpitha Banaji, et al.
Journal of Pharmaceutical Analysis (2021) Vol. 12, Iss. 1, pp. 58-64
Open Access | Times Cited: 13
Heterologous SARS‐CoV‐2 IgA neutralising antibody responses in convalescent plasma
Samantha K. Davis, Kevin J. Selva, Ester López, et al.
Clinical & Translational Immunology (2022) Vol. 11, Iss. 10
Open Access | Times Cited: 10
Nasal mucosal IgA levels against SARS-CoV-2 and seasonal coronaviruses are low in children but boosted by reinfection
Alexander C. Dowell, Gokhan Tut, Jusnara Begum, et al.
Journal of Infection (2023) Vol. 87, Iss. 5, pp. 403-412
Open Access | Times Cited: 5
Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2
Phillip Pymm, Samuel J. Redmond, Olan Dolezal, et al.
iScience (2022) Vol. 25, Iss. 11, pp. 105259-105259
Open Access | Times Cited: 9
Omicron variant losing its critical mutations in the receptor‐binding domain
Perumal Arumugam Desingu, K. Nagarajan
Journal of Medical Virology (2022) Vol. 94, Iss. 6, pp. 2365-2368
Open Access | Times Cited: 7
A flow cytometry-based neutralization assay for simultaneous evaluation of blocking antibodies against SARS-CoV-2 variants
Leire Egia‐Mendikute, Alexandre Bosch, Endika Prieto‐Fernández, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 7
Aggregation of high‐frequency RBD mutations of SARS‐CoV‐2 with three VOCs did not cause significant antigenic drift
Tao Li, Zhimin Cui, Yunfei Jia, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 5, pp. 2108-2125
Open Access | Times Cited: 5
SARS-CoV-2 Multi-Antigen Serology Assay
Ramin Mazhari, Shazia Ruybal‐Pesántez, Fiona Angrisano, et al.
Methods and Protocols (2021) Vol. 4, Iss. 4, pp. 72-72
Open Access | Times Cited: 6
Comparative magnitude and persistence of SARS-CoV-2 vaccination responses on a population level in Germany
Alex Dulovic, Barbora Kessel, Manuela Harries, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top